glp-1 study news Controversy surrounding diabetes drug, Ozempic, being used for weight loss Study: Most Patients Can Safely

Not the commercials

Purpose of Review This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor (GLP-1R) agonists, tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding indications in cardiovascular, renal, and metabolic health

A recently published, randomized, placebo-controlled trial found a greater reduction in BMI z-score (0.22 SDs) in adolescents receiving liraglutide compared with placebo

Purpose of Review To discuss current literature and provide practical recommendations for the safe and effective use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in people with inflammatory bowel disease (IBD) and type 2 diabetes (T2D) and/or obesity

Since the DRI per day is 25-30g, a smoothie with this claim would need to have at least 5g of fiber